EP Patent

EP2526094B1 — Substituted chlorocyclopentanols for therapeutic applications

Assigned to Allergan Inc · Expires 2016-05-25 · 10y expired

What this patent protects

Patent listed against Lumigan.

Drugs covered by this patent

Lumigan (BIMATOPROST)

Patent Metadata

Patent number: EP2526094B1
Jurisdiction: EP
Classification: —
Expires: 2016-05-25
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.